HAZLET, N.J. - s4story -- In this symposium, an expert faculty will discuss the data with injectable GLP-1 RAs in ASCVD patients and the place of injectable GLP-1 RAs in reduction of cardiovascular risk. The design, efficacy and safety results from the SOUL trial will be presented, as well as the latest meta-analyses with GLP-1 RAs. Cases of patients with T2D and ASCVD will be presented, and attendees will be provided with best practices incorporating evidence-based clinical decision making and patient-centered care.

Click here for more information

CHAIR

Darren McGuire, MD MHSC
Distinguished Chair in Cardiovascular Science
Distinguished Teaching Professor

More on S For Story

• Florida International University: "Psychiatry: An Industry of Death" Traveling Exhibit Educates Students on Mental Health Abuse
• CCHR: VA's Psychiatric Treatments Betray Veterans, Fuel Suicide and Death
• Integris Composites Named Armor Partner for U.S. Army's XM30 Combat Vehicle
• Jaipur Countryside, 4-Star Comfort: $199 for Two— All-Inclusive with Meals + Transfers at Heritage Hotel Savista
• New Series, The Library Saga, Starts With Two-Book Release

University of Texas Southwestern Medical Center
Dallas, Texas

FACULTY

Lawrence Letter, MD, FRCPC
Professor of Medicine and Nutritional Sciences
University of Toronto
Toronto, Ontario, Canada

Neha Pagidipati, MD, MPH
Associate Professor of Medicine
Duke University School of Medicine
Durham, North Carolina

Richard Pratley, MD
Samuel E. Crockett Chair in Diabetes Research
AdventHealth Translational Research Institute
Medical Director, AdventHealth Diabetes Institute
Orlando, Florida

Educational Objectives
- Describe the key injectable GLP-1 RA clinical trials and meta analyses in patients with T2D and high ASCVD risk
- Explain the American Diabetes Association 2025 guideline recommendations for the use of GLP-1 RAs in patients with T2D and ASCVD or multiple risk factors for ASCVD
- Interpret the evidence from the SOUL trial and describe the potential role for oral GLP-1 RA therapy in patients with T2D and high risk

Target Audience

More on S For Story

• Probate Shepherd® Announces a New Member Probate Attorney in Fort Worth, TX
• Phinge Announces "Test the Waters" Campaign for Potential Regulation A+ Offering: Home of Netverse Verified AI & Patented App-less Technology Platform
• Oliver Sean's Book The Noise I Make Becomes a Multi-Category Bestseller on Amazon Hot New Releases
• New Book Offers Hope for Those Suffering from "Chewing Rage" Misophonia
• RJ Grimshaw Launches "The AI EDGE" A Practical Guide Where Leadership Meets Innovation

This program is intended for cardiovascular clinicians and other healthcare professionals who manage patients with T2D and ASCVD risk.

Educational Grant
Voxmedia International gratefully acknowledges the educational grant from Novo Nordisk Inc.

Accreditation and Credit Designation Statements
Voxmedia, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Voxmedia, LLC designates this live activity for a maximum of 1.5 AMA PRA Category Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.